Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 3381 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
  Instructions 
  Search 
  IPS 
  My preferences 

 


This article has been cited by
1Genetic Variants of Microsomal Triglyceride Transfer Protein (MTTP) Are Associated With Metabolic Syndrome in Schizophrenic Patients Treated With Atypical Antipsychotics
Ying-Jay Liou,Shih-Jen Tsai,Ying-Chieh Wang,Ya Mei Bai,Chen-Jee Hong
Journal of Clinical Psychopharmacology.2013;33(3)313
[DOI]
2Prevalence and predictors of metabolic syndrome in patients with schizophrenia and healthy controls: A study in rural South Indian population
Vikram Singh Rawat,Suhas Ganesh,Somashekar Bijjal,K. Shanivaram Reddy,Vikas Agarwal,Renuka Devi,Chennaveerachari Naveen Kumar,Rita Christopher,Jagadisha Thirthalli
Schizophrenia Research.2018;192(3)102
[DOI]
3Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy
Kyle J. Burghardt,Vicki L. Ellingrod
Molecular Diagnosis & Therapy.2013;17(1)21
[DOI]
4“First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects
Su Ling Young,Mark Taylor,Stephen M Lawrie
Journal of Psychopharmacology.2015;29(4)353
[DOI]
5Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes
Tomomi Tsubai,Akira Yoshimi,Yoji Hamada,Makoto Nakao,Hiroshi Arima,Yutaka Oiso,Yukihiro Noda
Journal of Pharmacological Sciences.2017;133(2)79
[DOI]
6Impacts of 2012 update to the AGS beers criteria on potentially inappropriate antipsychotic medication use among older adults
Dooyoung Lim,Darren Liu,Betty Burston
Aging and Health Research.2021;1(3)100025
[DOI]
7Toxicology and Overdose of Atypical Antipsychotics
Alicia B. Minns,Richard F. Clark
The Journal of Emergency Medicine.2012;43(5)906
[DOI]
8The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study
Samer Hammoudeh,Suhaila Ghuloum,Ziyad Mahfoud,Arij Yehya,Abdulmoneim Abdulhakam,Azza Al-Mujalli,Mahmoud Al-Zirie,Mohamed Osman Abdel Rahman,Angela Godwin,Noura Younes,Yahya Hani,Dennis Mook-Kanamori,Marjonneke Mook-Kanamori,Reem El Sherbiny,Hassen Al-Amin
BMC Psychiatry.2018;18(1)906
[DOI]
910-year CVD risk in Han Chinese mainland patients with schizophrenia
Shuai Zhao,HaiLong Xia,JingJing Mu,Long Wang,Li Zhu,AnZhen Wang,XiaoQin Zhou
Psychiatry Research.2018;264(1)322
[DOI]
1010-year CVD risk in Han Chinese mainland patients with schizophrenia
Parmanand Kulhara,Sandeep Grover,Natasha Kate
Psychiatry Research.2015;264(1)173
[DOI]
11Schizophrenia and folate pharmacogenetics: Review of the literature regarding folic acid and its pharmacogenetically regulated metabolism in relation to schizophrenia treatments
Andrew Wechter,Kristen N. Gardner,Tyler B. Grove,Vicki L. Ellingrod
Mental Health Clinician.2012;1(9)225
[DOI]
12Prevalence and determinants of metabolic syndrome in patients with schizophrenia: A systematic review and meta-analysis of Indian studies
Suhas Ganesh,Abhishekh Hulegar Ashok,Chennaveerachari Naveen Kumar,Jagadish Thirthalli
Asian Journal of Psychiatry.2016;22(9)86
[DOI]
13METABOLIC SIDE EFFECTS OF HALOPERIDOL AND RISPERIDONE- A SIX MONTHS FOLLOWUP STUDY
Kalaimathi B,Mohamed Ilyas Rahamathulla M,Mohana Lakshmi M,Alexander Gnana Durai W.J,Saravana Jothi R,Priyadharshini R,Jeevitha K
Journal of Evidence Based Medicine and Healthcare.2017;3(25)1463
[DOI]
14A Study of Metabolic Syndrome in Patients on Risperidone
Ajay Thangraj,Nimesh G. Desai,Vijender Singh
Current Psychopharmacology.2020;9(3)218
[DOI]
15Early Detection of Metabolic Abnormalities in Patients with Newly Diagnosed Schizophrenia on Atypical Antipsychotics
Rochlani D,Lahariya S,Bansal S.K
Journal of Evolution of Medical and Dental Sciences.2019;8(43)3229
[DOI]
16Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia
Yi Hang Tay,Milawaty Nurjono,Jimmy Lee
Schizophrenia Research.2013;147(1)187
[DOI]
17The prevalence of mental health medication use in a cohort of New Zealand patients with diabetes
Lynne Chepulis,Brittany Morison,Chunhuan Lao,Rawiri Keenan,Ryan Paul,Ross Lawrenson
Primary Care Diabetes.2020;14(6)703
[DOI]
18Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis
Rong Li,Yiqi Zhang,Wenqiang Zhu,Chen Ding,Wenjie Dai,Xin Su,Wen Dai,Jingmei Xiao,Zhenhua Xing,Xiansheng Huang
Scientific Reports.2020;10(1)703
[DOI]
19Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment
Adrian L. Lopresti,Peter D. Drummond
Progress in Neuro-Psychopharmacology and Biological Psychiatry.2013;45(1)92
[DOI]
20Obesity, adipokines and neuroinflammation
Argel Aguilar-Valles,Wataru Inoue,Christoph Rummel,Giamal N. Luheshi
Neuropharmacology.2015;96(1)124
[DOI]
21Metabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies
Sandeep Grover,Naresh Nebhinani,Ramachandran Padmavati,Rakesh K Chadda,Srinivasan Tirupati,Abhishek Pallava
Early Intervention in Psychiatry.2015;9(5)357
[DOI]
22Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine
Nancy Monroy-Jaramillo,Yaneth Rodríguez-Agudelo,Luis Carlos Aviña-Cervantes,David L. Roberts,Dawn I. Velligan,Consuelo Walss-Bass
Journal of Psychiatric Research.2017;90(5)26
[DOI]